Navigation Links
Select Medical Holdings Corporation Announces Exercise of Underwriters' Option to Purchase Additional Shares
Date:10/24/2009

MECHANICSBURG, Pa., Oct. 23 /PRNewswire-FirstCall/ -- Select Medical Holdings Corporation ("Select") (NYSE: SEM), the parent of Select Medical Corporation, today announced that it had received notice of the exercise of the underwriters' over-allotment option to purchase an additional 3,602,700 shares of Select's common stock at a price per share of $10.00, which is expected to close on October 28, 2009, subject to customary closing conditions. The over-allotment option was granted in connection with Select's initial public offering of 30,000,000 shares, which closed on September 30, 2009.

Total additional net proceeds to Select from the exercise of the over-allotment option are expected to be approximately $33.9 million. Select intends to use the net proceeds from the exercise of the over-allotment option to repay indebtedness. Any remaining net proceeds will be used for general corporate purposes.

Goldman, Sachs & Co., Morgan Stanley & Co. Incorporated, BofA Merrill Lynch and J.P. Morgan Securities Inc. acted as joint book-runners for the offering.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. A copy of the final prospectus related to the offering may be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 85 Broad St., New York, NY 10004 or by faxing (212) 902-9316 or calling toll-free 1-866-471-2526 or emailing at prospectus - ny@ny.email.gs.com; or Morgan Stanley & Co. Incorporated, Attention: Prospectus Department, 180 Varick Street, New York, New York 10014 (email address: prospectus@morganstanley.com); or BofA Merrill Lynch, 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department; or J.P. Morgan Securities Inc., Attention: Prospectus Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, or by calling (718) 242-8002.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made solely by means of a prospectus.

About Select

Select is a leading operator of specialty hospitals in the United States. As of September 30, 2009, Select operated 89 long term acute care hospitals and five acute medical rehabilitation hospitals in 25 states, and 947 outpatient rehabilitation clinics in 37 states and the District of Columbia. Select also provides medical rehabilitation services on a contracted basis to nursing homes, hospitals, assisted living and senior care centers, schools and work sites. Information about Select is available at http://www.selectmedicalcorp.com

SOURCE Select Medical Holdings Corporation


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring
2. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
3. A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
4. Sharp HealthCare Selects MEDais Pinpoint Review to Prevent Readmissions
5. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
6. Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution
7. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
8. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
9. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
10. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
11. Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):